Dr Reddy’s aims for US Copaxone launch

Dr Reddy’s Laboratories is aiming to launch generic Copaxone (glatiramer acetate) in the US in the first half of its next financial year ending March 2020, chief operating officer Erez Israeli has revealed.

Dr Reddy’s Laboratories is aiming to launch generic Copaxone (glatiramer acetate) in the US in the first half of its next financial year ending March 2020, chief operating officer Erez Israeli has revealed.

Acknowledging the firm had previously received queries from the US Food and Drug Administration (FDA) over its glatiramer acetate drug...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business